fda semaglutide shortage resolved 2025 announcement Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list The FDA Removes Semaglutide from

Direct effects on the sinoatrial node or cardiac tissue may also play a role, as GLP-1 receptors have been identified in cardiac tissue

Using Wegovy for about 4 weeks now and not only the product itself is fantastic, but the service from MedExpress is fantastic from consultation, ordering, delivery, re-ordering reminders

And it remains far from pharmaceutical marketing: Phase 3 trials are underway, the target NDA is Q4 2026, and patient access is theoretically not expected before 2028-2029

It generally continues unchanged during the switch because it works through an entirely different mechanism (reducing hepatic glucose production) and does not interact with incretin receptors